Regulus Therapeutics (RGLS) Stock: Falling On Double Dose Of Bad News


Regulus Therapeutics Inc (NASDAQ: RGLS)

Regulus Therapeutics is having a rough day in the market today, and for good reason. There was a double whammy of bad news released with regard to the company that’s causing the declines. Today, we’ll talk about the news, what we’re seeing from the stock, and what we can expect to see from RGLS ahead.

RGLS Gets Hit With Double Dose Of Bad News

As mentioned above, Regulus Therapeutics is having a bad day in the market today after two big pieces of bad news are weighing heavy on the stock. Here’s the news…

  • RG-101 HVC: This is a treatment that was getting ready for an FDA submission. However, today, RGLS investors learned that there would be a delay in submission involving a clinical hold.
  • RG-012 Alport: Unfortunately, this is another bit of bad news for RGLS investors. The trial involved in RG-012 has suspended dosing. It is now stepping backward to healthy volunteers.

How The Stock Reacted To The News

As investors, we know that the news moves the market. Unfortunately, the news surrounding Regulus Therapeutics was anything but positive. As a result, we’re seeing steep declines in the value of the stock today. Currently (2:34), RGLS is trading at $2.59 per share after a loss of $0.21 per share or 7.66% thus far today.

What We’ll Be Watching Ahead

The news released with regard to RGLS today was overwhelmingly negative. However, the figurative fat lady has not yet sung. While these drugs are going backward, they are not stopping development, so, there’s still promise here. Nonetheless, we will be watching Regulus Therapeutics very closely and warn investors of risks associated with moving in here.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

[adrotate group=”4″]

[Image Courtesy of Pixabay]


Please enter your comment!
Please enter your name here